ImpedimedASX:IPD Days Payable is 338.98 as of Dec. 2025, which is 21% below its 10-year median of 427.52. The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Impedimed ranks better than 89.43% on this metric.
Impedimed's average Accounts Payable for the
six
months ended in Dec. 2025 was A$1.75 Mil. Impedimed's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$0.94 Mil.
Hence, Impedimed's Days Payable for the
six
months ended in Dec. 2025 was 338.98.
The historical rank and industry rank for Impedimed's Days Payable or its related term are showing as below:
ASX:IPD'
s Days Payable Range Over the Past 10 Years
Min: 224.76 Med: 427.52 Max: 670.82
Current: 311.76
During the past 13 years, Impedimed's highest Days Payable was 670.82. The lowest was 224.76. And the median was 427.52.
ASX:IPD's Days Payable is ranked better than 89.43% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs ASX:IPD: 311.76
Impedimed's Days Payable
increased
from Dec. 2024 (338.15) to Dec. 2025 (338.98).
It may suggest that Impedimeddelayed paying its suppliers.
Impedimed Days Payable Related Terms
Impedimed Days Payable Historical Data
* Premium members only.
The historical data trend for Impedimed's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Impedimed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impedimed Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's Days Payable distribution charts can be found below:
* The bar in red indicates where Impedimed's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Impedimed's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impedimed (ASX:IPD) has a Days Payable of 338.98 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Impedimed and its competitors. This is 21% below median its historical median of 427.52. Over the past decade, Impedimed's Days Payable has ranged from 224.76 to 670.82. According to the industry distribution chart, Impedimed ranks #84 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 10.6%.
Is Impedimed's Days Payable too high?
Impedimed's current Days Payable of 338.98 is 21% below median its 10-year median of 427.52. Over the past 10 years, this metric has ranged from a low of 224.76 to a high of 670.82. The Medical Devices & Instruments industry median Days Payable is 67.87. Impedimed's value of 338.98 is 399.5% above this industry median. Based on the distribution chart, Impedimed ranks #84 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Impedimed's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #84 out of 795 companies for Days Payable. This places Impedimed in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.87. Impedimed's value of 338.98 is 399.5% above this benchmark. Historically, Impedimed's own Days Payable has ranged from 224.76 to 670.82 over the past decade. While the company's 10-year median is 427.52 vs. the industry median of 67.87, Impedimed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Impedimed's current Days Payable of 338.98 is 399.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Impedimed and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current Days Payable is 338.98, which is 21% below median its own 10-year median of 427.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 93.8% below its estimated fair value. The current Days Payable is 338.98, which is 21% below median its 10-year median of 427.52 and 399.5% above the Medical Devices & Instruments industry median of 67.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Days Payable is 338.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 